Bright Light Therapy During Residential Alcohol Withdrawal

Last updated: March 11, 2025
Sponsor: Centre Hospitalier St Anne
Overall Status: Active - Recruiting

Phase

N/A

Condition

Substance Abuse

Alcohol Use Disorder

Alcohol Dependence

Treatment

Light exposure

Placebo light

Clinical Study ID

NCT06878287
D20-P49
  • Ages 18-65
  • All Genders

Study Summary

This is a randomized controlled trial assessing the effectiveness of light therapy versus placebo in patients undergoing alcohol withdrawal.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients must be aged from 18 to 65 years old and have a diagnosis of Alcohol UseDisorder

  • Patients must be intreated for alcohol withdrawal, for at least two weeks

  • Patients must report heavy drinking episodes in the past month

  • Patients must be able to understand medical information and consent to the treatment

  • Patients must be considering a goal of abstinence from alcohol

Exclusion

Exclusion Criteria:

  • Ophthalmic pathology (cataract, macular degeneration, glaucoma, retinitispigmentosa) and diseases affecting the retina (retinopathy, diabetes, herpes, etc.)

  • Subjects who have already received light therapy in the last 6 months

  • Lactating of pregnant women

  • Psychiatric comorbidity requiring an intreatment, or risk of manic episode (subjectswith depressive or anxious symptoms compatible with an out-treatment can beincluded)

  • Substance Use Disorder other than alcohol and/or tobacco

  • Severe cognitive impairment (MOCA < 10)

  • Patients being under legal protection measure

Study Design

Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Light exposure
Phase:
Study Start date:
May 31, 2022
Estimated Completion Date:
May 31, 2025

Study Description

All eligible patients will be offered and explained the study by a psychiatrist/addictologist during the consultation (or teleconsultation) to schedule a 14-day hospitalization for alcohol withdrawal (maximum 3 months before hospitalization). Patients will be randomized centrally to one of the following two treatment conditions (blind maintained by a nurse independent of the assessment), on day D0 of inpatient treatment for withdrawal (standardized withdrawal over 14 days with hydration, vitamin B1, benzodiazepines in gradual decrease before stopping and according to signs of withdrawal):

  1. Active light therapy (10,000 Lux).

  2. Placebo light therapy (with filter <10 Lux). Every morning in the room (patient in a single room), at 8 am, for 30 min, for the entire duration of withdrawal, i.e. 13 days (start on D1) and stopped on D14.

No change in usual care apart from this intervention.

After checking the inclusion and non-inclusion criteria and obtaining consent, patients will be randomized (ratio 1:1) between the groups with active light therapy or placebo, by connecting to a randomization website (REDCap software) using a randomization list prepared in advance, balanced by block of randomly variable size

Connect with a study center

  • Adult Emergency Department - Bichât Hospital

    Paris, Île-de-France 75018
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.